American Journal of Cardiovascular Drugs

, Volume 10, Issue 4, pp 239–246

Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension

A Randomized, Double-Blind, Placebo-Controlled Study

Authors

    • The Christ Hospital Heart and Vascular Center/The Carl and Edyth Lindner Center for Research and EducationThe Christ Hospital
  • Jen-Fue Maa
    • Daiichi Sankyo, Inc.
  • Ali Shojaee
    • Daiichi Sankyo, Inc.
  • Robert Dubiel
    • Daiichi Sankyo, Inc.
Original Research Article

DOI: 10.2165/11538630-000000000-00000

Cite this article as:
Kereiakes, D.J., Maa, J., Shojaee, A. et al. Am J Cardiovasc Drugs (2010) 10: 239. doi:10.2165/11538630-000000000-00000

Abstract

Background and Objective

Elevated systolic BP (SBP) is a major contributor to cardiovascular disease. SBP control reduces the occurrence of stroke, heart failure, and cardiovascular and total mortality. The aim of this study was to analyze the magnitude of SBP reductions and the achievement of individual SBP targets in the original BENIFORCE study.

Methods

An olmesartan medoxomil-based treatment algorithm was evaluated in a double-blind, placebo-controlled titration study in 276 patients with stage 1 (47.1%) or 2 (52.9%) hypertension. After placebo run-in, patients were randomized to placebo (12 weeks) or olmesartan medoxomil 20 mg/day (weeks 1–3). Olmesartan medoxomil was uptitrated to 40 mg/day (weeks 4–6), then olmesartan medoxomil/hydrochlorothiazide (HCTZ) 40/12.5 mg per day (weeks 7–9), and olmesartan medoxomil/HCTZ 40/25 mg per day (weeks 10–12) if BP remained ≥120/80 mmHg at any time interval.

Setting

The BENIFORCE study was a multicenter (29 sites) study conducted between January and October 2007 in the US.

Results

In patients receiving olmesartan medoxomil-based therapy, 81.0%, 67.2%, and 46.6% of patients with stage 1 hypertension and 70.4%, 49.4%, and 23.5% of patients with stage 2 hypertension achieved SBP targets of <140, <130, and <120 mmHg, respectively (all p<0.01 vs placebo). The proportions of patients achieving SBP targets increased with escalating doses of olmesartan medoxomil and HCTZ, administered alone or in combination, and was highest for combination therapy. Similarly, escalating doses of olmesartan medoxomil or olmesartan medoxomil/HCTZ increased the proportion of patients achieving SBP reductions of >15 but ≤30, >30 but ≤45, and >45 mmHg compared with placebo.

Conclusion

An olmesartan medoxomil-based treatment algorithm effectively reduced SBP and achieved SBP targets in patients with stage 1 or 2 hypertension. This regimen resulted in >80% of patients achieving SBP reductions of ≥15 mmHg while 44% achieved SBP reductions of >30 mmHg.

Copyright information

© Adis Data Information BV 2010